vimarsana.com

Page 397 - தொழில் முனைவோர் மகேந்திரா நாத் பாண்டே News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Commissioners to move ahead with water line projects

Applications filed in 19 nations for protection of GI, certification mark for Basmati: Puri

Applications filed in 19 nations for protection of GI, certification mark for Basmati: Puri SECTIONS Last Updated: Mar 10, 2021, 09:08 PM IST Share Synopsis A law firm has been engaged to initiate and deal with the consequential legal matters for the protection of GI/ Certification Mark for Basmati , both in India and foreign jurisdictions. Agencies Applications have been filed in 19 foreign jurisdictions for protection of GI/ Certification Mark vested in Basmati, he said. Applications have been filed in as many as 19 foreign jurisdictions for protection of Geographical Indicator and Certification Mark for Basmati rice, Parliament was informed on Wednesday. In a written reply to a query in the Lok Sabha, Minister of State for Commerce and Industry Hardeep Singh Puri said that so far, Certification Mark for Basmati and its logo have been registered in four countries - UK, South Africa, New Zealand and Kenya.

PrintWeek India magazine latest issue, archive, subscription

Sewage plant upgrades are needed to achieve discharge compliance, study says

Despite dedicated problem solving by the city’s public works department, the Driggs City Council learned this month that the wastewater treatment facility is still discharging too much ammonia and the

XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights

Published: Mar 10, 2021 Recognized revenue of $29.4 million  Six assets in the Company’s milestone and royalty portfolio advanced to Phase 2 clinical development  Completed $24.6 million Series A Perpetual Preferred Stock offering paying a 8.625% dividend  Ended 2020 with $84.2 million in cash EMERYVILLE, Calif., March 10, 2021 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA) announced its fourth quarter and full-year 2020 financial results and business highlights. “Our success in 2020 is a direct reflection of our strategy at work.  As a result of the commitment by our partners to improve human health, we saw multiple programs advance further in the clinic.  Novartis, Merck, Takeda, Incyte, Rezolute, and an undisclosed partner individually launched Phase 2 clinical studies with an asset in the XOMA portfolio.  XOMA’s shareholders benefited from the milestones we received as our partners made these advancements, highlighted by the $25 million milestone we ear

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.